{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T17:17:15Z","timestamp":1775841435148,"version":"3.50.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Special Account for Research Funds (Eidikos Logariasmos Kondilion Erevnas; ELKE) of Aristotle University of Thessaloniki, Thessaloniki, Greece","award":["ID: 75279"],"award-info":[{"award-number":["ID: 75279"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hormones"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s42000-024-00621-3","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T05:06:11Z","timestamp":1734584771000},"page":"419-431","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Limited preventive effects of empagliflozin against metabolic dysfunction-associated steatotic liver disease in a mouse model of fast food diet"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3177-2129","authenticated-orcid":false,"given":"Evangelia S.","family":"Makri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantinos","family":"Xanthopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Spyros","family":"Pettas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonis","family":"Goulas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panagiotis","family":"Mavrommatis-Parasidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleftheria","family":"Makri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastasia","family":"Tsingotjidou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angeliki","family":"Cheva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charikleia","family":"Ntenti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constantinos K.","family":"Zacharis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iris","family":"Ballaouri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Spyridon","family":"Gerou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stergios A.","family":"Polyzos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,19]]},"reference":[{"issue":"10","key":"621_CR1","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1016\/j.cgh.2024.03.006","volume":"22","author":"ZM Younossi","year":"2024","unstructured":"Younossi ZM, Golabi P, Price JK, Owrangi S, Gundu-Rao N, Satchi R, Paik J (2024) The global epidemiology of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis among patients with type 2 diabetes. Clin Gastroenterol Hepatol. 22(10):1999-2010.e8","journal-title":"Clin Gastroenterol Hepatol."},{"key":"621_CR2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.arcmed.2020.11.010","volume":"52","author":"E Makri","year":"2021","unstructured":"Makri E, Goulas A, Polyzos SA (2021) Epidemiology, pathogenesis, diagnosis and emerging treatment of nonalcoholic fatty liver disease. Arch Med Res 52:25\u201337","journal-title":"Arch Med Res"},{"key":"621_CR3","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.jhep.2016.05.013","volume":"65","author":"G Targher","year":"2016","unstructured":"Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C (2016) Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol 65:589\u2013600","journal-title":"J Hepatol"},{"key":"621_CR4","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.metabol.2015.12.009","volume":"65","author":"SA Polyzos","year":"2016","unstructured":"Polyzos SA, Mantzoros CS (2016) Nonalcoholic fatty future disease. Metabolism 65:1007\u20131016","journal-title":"Metabolism"},{"key":"621_CR5","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1016\/j.dsx.2020.09.030","volume":"14","author":"E Makri","year":"2020","unstructured":"Makri E, Kita M, Goulas A, Papaioannidou P, Efstathiadou ZA, Adamidou F, Polyzos SA (2020) Comparative effectiveness of glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors on noninvasive indices of hepatic steatosis and fibrosis in patients with type 2 diabetes mellitus. Diabetes Metab Syndr 14:1913\u20131919","journal-title":"Diabetes Metab Syndr"},{"key":"621_CR6","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.3390\/jpm12071166","volume":"12","author":"ES Makri","year":"2022","unstructured":"Makri ES, Makri E, Polyzos SA (2022) Combination therapies for nonalcoholic fatty liver disease. J Pers Med 12:1166","journal-title":"J Pers Med"},{"key":"621_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.174272","volume":"907","author":"ES Makri","year":"2021","unstructured":"Makri ES, Goulas A, Polyzos SA (2021) Sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease. Eur J Pharmacol 907:174272","journal-title":"Eur J Pharmacol"},{"key":"621_CR8","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1007\/s13300-019-0657-8","volume":"10","author":"A Ali","year":"2019","unstructured":"Ali A, Bain S, Hicks D, Newland Jones P, Patel DC, Evans M, Fernando K, James J, Milne N, Viljoen A, Wilding J (2019) SGLT2 inhibitors: cardiovascular benefits beyond HbA1c-translating evidence into practice. Diabetes Ther 10:1595\u20131622","journal-title":"Diabetes Ther"},{"key":"621_CR9","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1681\/ASN.0000000000000271","volume":"35","author":"KJ Mayne","year":"2024","unstructured":"Mayne KJ, Staplin N, Keane DF, Wanner C, Brenner S, Cejka V, Stegbauer J, Judge PK, Preiss D, Emberson J, Trinca D, Dayanandan R, Lee R, Nolan J, Omata A, Green JB, Cherney DZI, Hooi LS, Pontremoli R, Tuttle KR, Lees JS, Mark PB, Davies SJ, Hauske SJ, Steubl D, Br\u00fcckmann M, Landray MJ, Baigent C, Haynes R, Herrington WG (2024) Effects of empagliflozin on fluid overload, weight, and blood pressure in CKD. J Am Soc Nephrol 35:202\u2013215","journal-title":"J Am Soc Nephrol"},{"key":"621_CR10","doi-asserted-by":"publisher","first-page":"1144838","DOI":"10.3389\/fendo.2023.1144838","volume":"14","author":"P Zhou","year":"2023","unstructured":"Zhou P, Tan Y, Hao Z, Xu W, Zhou X, Yu J (2023) Effects of SGLT2 inhibitors on hepatic fibrosis and steatosis: a systematic review and meta-analysis. Front Endocrinol (Lausanne) 14:1144838","journal-title":"Front Endocrinol (Lausanne)"},{"key":"621_CR11","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.3390\/medicina59061136","volume":"59","author":"IC Bica","year":"2023","unstructured":"Bica IC, Stoica RA, Salmen T, Jane\u017e A, Vol\u010dan\u0161ek \u0160, Popovic D, Muzurovic E, Rizzo M, Stoian AP (2023) The effects of sodium-glucose cotransporter 2-inhibitors on steatosis and fibrosis in patients with non-alcoholic fatty liver disease or steatohepatitis and type 2 diabetes: a systematic review of randomized controlled trials. Medicina (Kaunas) 59:1136","journal-title":"Medicina (Kaunas)"},{"key":"621_CR12","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12933-018-0750-8","volume":"17","author":"AR Aroor","year":"2018","unstructured":"Aroor AR, Das NA, Carpenter AJ, Habibi J, Jia G, Ramirez-Perez FI, Martinez-Lemus L, Manrique-Acevedo CM, Hayden MR, Duta C, Nistala R, Mayoux E, Padilla J, Chandrasekar B, DeMarco VG (2018) Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury. Cardiovasc Diabetol 17:108","journal-title":"Cardiovasc Diabetol"},{"key":"621_CR13","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12933-019-0816-2","volume":"18","author":"C Li","year":"2019","unstructured":"Li C, Zhang J, Xue M, Li X, Han F, Liu X, Xu L, Lu Y, Cheng Y, Li T, Yu X, Sun B, Chen L (2019) SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. Cardiovasc Diabetol 18:15","journal-title":"Cardiovasc Diabetol"},{"key":"621_CR14","doi-asserted-by":"publisher","first-page":"G825","DOI":"10.1152\/ajpgi.00145.2011","volume":"301","author":"M Charlton","year":"2011","unstructured":"Charlton M, Krishnan A, Viker K, Sanderson S, Cazanave S, McConico A, Masuoko H, Gores G (2011) Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition. Am J Physiol Gastrointest Liver Physiol 301:G825-834","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"621_CR15","unstructured":"Charlton M, Krishnan A, Viker K, Sanderson S, Cazanave S, McConico A, Masuoko H, Gores G (2015) Corrigendum in: Fast food diet mouse: novel small animal model of NASH with ballooning, progressivefibrosis, and high physiological fidelity to the human condition. Am J Physiol Gastrointest Liver Physiol 308:G159"},{"key":"621_CR16","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1007\/s12020-024-03769-5","volume":"85","author":"ES Makri","year":"2024","unstructured":"Makri ES, Xanthopoulos K, Mavrommatis Parasidis P, Makri E, Pettas S, Tsingotjidou A, Cheva A, Ballaouri I, Gerou S, Goulas A, Polyzos SA (2024) Partial validation of a six-month high-fat diet and fructose-glucose drink combination as a mouse model of nonalcoholic fatty liver disease. Endocrine 85:704\u2013716","journal-title":"Endocrine"},{"key":"621_CR17","doi-asserted-by":"publisher","first-page":"e3000410","DOI":"10.1371\/journal.pbio.3000410","volume":"18","author":"N Percie du Sert","year":"2020","unstructured":"Percie du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, Browne WJ, Clark A, Cuthill IC, Dirnagl U, Emerson M, Garner P, Holgate ST, Howells DW, Karp NA, Lazic SE, Lidster K, MacCallum CJ, Macleod M, Pearl EJ, Petersen OH, Rawle F, Reynolds P, Rooney K, Sena ES, Silberberg SD, Steckler T, W\u00fcrbel H (2020) The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. PLoS Biol 18:e3000410","journal-title":"PLoS Biol"},{"key":"621_CR18","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1177\/0023677217724823","volume":"52","author":"AJ Smith","year":"2018","unstructured":"Smith AJ, Clutton RE, Lilley E, Hansen KEA, Brattelid T (2018) PREPARE: guidelines for planning animal research and testing. Lab Anim 52:135\u2013141","journal-title":"Lab Anim"},{"key":"621_CR19","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/BF00280883","volume":"28","author":"DR Matthews","year":"1985","unstructured":"Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412\u2013419","journal-title":"Diabetologia"},{"key":"621_CR20","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41:1313\u20131321","journal-title":"Hepatology"},{"key":"621_CR21","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3390\/biomedicines9040353","volume":"9","author":"KL Hupa-Breier","year":"2021","unstructured":"Hupa-Breier KL, Dywicki J, Hartleben B, Wellh\u00f6ner F, Heidrich B, Taubert R, Mederacke YE, Lieber M, Iordanidis K, Manns MP, Wedemeyer H, Hardtke-Wolenski M, Jaeckel E (2021) Dulaglutide alone and in combination with empagliflozin attenuate inflammatory pathways and microbiome dysbiosis in a non-diabetic mouse model of NASH. Biomedicines 9:353","journal-title":"Biomedicines"},{"key":"621_CR22","doi-asserted-by":"publisher","first-page":"6332","DOI":"10.3390\/ijms22126332","volume":"22","author":"N Perakakis","year":"2021","unstructured":"Perakakis N, Chrysafi P, Feigh M, Veidal SS, Mantzoros CS (2021) Empagliflozin improves metabolic and hepatic outcomes in a non-diabetic obese biopsy-proven mouse model of advanced NASH. Int J Mol Sci 22:6332","journal-title":"Int J Mol Sci"},{"key":"621_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114445","volume":"161","author":"DY Kim","year":"2023","unstructured":"Kim DY, Chung KS, Park JY, Gee HY (2023) Preventive effect of empagliflozin and ezetimibe on hepatic steatosis in adults and murine models. Biomed Pharmacother 161:114445","journal-title":"Biomed Pharmacother"},{"key":"621_CR24","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13098-016-0169-x","volume":"8","author":"T Jojima","year":"2016","unstructured":"Jojima T, Tomotsune T, Iijima T, Akimoto K, Suzuki K, Aso Y (2016) Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes. Diabetol Metab Syndr 8:45","journal-title":"Diabetol Metab Syndr"},{"key":"621_CR25","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.bbrc.2021.12.065","volume":"588","author":"N Lee","year":"2022","unstructured":"Lee N, Heo YJ, Choi SE, Jeon JY, Han SJ, Kim DJ, Kang Y, Lee KW, Kim HJ (2022) Hepatoprotective effects of gemigliptin and empagliflozin in a murine model of diet-induced non-alcoholic fatty liver disease. Biochem Biophys Res Commun 588:154\u2013160","journal-title":"Biochem Biophys Res Commun"},{"key":"621_CR26","doi-asserted-by":"publisher","first-page":"11513","DOI":"10.3390\/ijms222111513","volume":"22","author":"M H\u00fcttl","year":"2021","unstructured":"H\u00fcttl M, Markova I, Miklankova D, Zapletalova I, Poruba M, Haluzik M, Van\u011b\u010dkova I, Malinska H (2021) In a prediabetic model, empagliflozin improves hepatic lipid metabolism independently of obesity and before onset of hyperglycemia. Int J Mol Sci 22:11513","journal-title":"Int J Mol Sci"},{"key":"621_CR27","doi-asserted-by":"publisher","first-page":"818","DOI":"10.3390\/ijms22020818","volume":"22","author":"N Nasiri-Ansari","year":"2021","unstructured":"Nasiri-Ansari N, Nikolopoulou C, Papoutsi K, Kyrou I, Mantzoros CS, Kyriakopoulos G, Chatzigeorgiou A, Kalotychou V, Randeva MS, Chatha K, Kontzoglou K, Kaltsas G, Papavassiliou AG, Randeva HS, Kassi E (2021) Empagliflozin attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) in high fat diet fed ApoE((-\/-)) mice by activating autophagy and reducing ER stress and apoptosis. Int J Mol Sci 22:818","journal-title":"Int J Mol Sci"},{"key":"621_CR28","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1007\/s00125-022-05851-x","volume":"66","author":"B Radlinger","year":"2023","unstructured":"Radlinger B, Ress C, Folie S, Salzmann K, Lechuga A, Weiss B, Salvenmoser W, Graber M, Hirsch J, Holfeld J, Kremser C, Moser P, Staudacher G, Jelenik T, Roden M, Tilg H, Kaser S (2023) Empagliflozin protects mice against diet-induced obesity, insulin resistance and hepatic steatosis. Diabetologia 66:754\u2013767","journal-title":"Diabetologia"},{"key":"621_CR29","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/s42255-024-01043-6","volume":"6","author":"M Vacca","year":"2024","unstructured":"Vacca M, Kamzolas I, Harder LM, Oakley F, Trautwein C, Hatting M, Ross T, Bernardo B, Oldenburger A, Hjuler ST, Ksiazek I, Lind\u00e9n D, Schuppan D, Rodriguez-Cuenca S, Tonini MM, Casta\u00f1eda TR, Kannt A, Rodrigues CMP, Cockell S, Govaere O, Daly AK, Allison M, Honnens de Lichtenberg K, Kim YO, Lindblom A, Oldham S, Andr\u00e9asson A-C, Schlerman F, Marioneaux J, Sanyal A, Afonso MB, Younes R, Amano Y, Friedman SL, Wang S, Bhattacharya D, Simon E, Paradis V, Burt A, Grypari IM, Davies S, Driessen A, Yashiro H, Pors S, Worm Andersen M, Feigh M, Yunis C, Bedossa P, Stewart M, Cater HL, Wells S, Schattenberg JM, Anstee QM, Anstee QM, Daly AK, Cockell S, Tiniakos D, Bedossa P, Burt A, Oakley F, Cordell HJ, Day CP, Wonders K, Missier P, McTeer M, Vale L, Oluboyede Y, Breckons M, Boyle J, Bossuyt PM, Zafarmand H, Vali Y, Lee J, Nieuwdorp M, Holleboom AG, Angelakis A, Verheij J, Ratziu V, Cl\u00e9ment K, Patino-Navarrete R, Pais R, Paradis V, Schuppan D, Schattenberg JM, Surabattula R, Myneni S, Kim YO, Straub BK, Vidal-Puig A, Vacca M, Rodrigues-Cuenca S, Allison M, Kamzolas I, Petsalaki E, Campbell M, Lelliott CJ, Davies S, Ore\u0161i\u010d M, Hy\u00f6tyl\u00e4inen T, McGlinchey A, Mato JM, Millet \u00d3, Dufour J-F, Berzigotti A, Masoodi M, Lange NF, Pavlides M, Harrison S, Neubauer S, Cobbold J, Mozes F, Akhtar S, Olodo-Atitebi S, Banerjee R, Shumbayawonda E, Dennis A, Andersson A, Wigley I, Romero-G\u00f3mez M, G\u00f3mez-Gonz\u00e1lez E, Ampuero J, Castell J, Gallego-Dur\u00e1n R, Fern\u00e1ndez-Lizaranzu I, Montero-Vallejo R, Karsdal M, Rasmussen DGK, Leeming DJ, Sinisi A, Musa K, Sandt E, Tonini MM, Bugianesi E, Rosso C, Armandi A, Marra F, Gastaldelli A, Svegliati G, Boursier J, Francque S, Vonghia L, Verrijken A, Dirinck E, Driessen A, Ekstedt M, Kechagias S, Yki-J\u00e4rvinen H, Porthan K, Arola J, van Mil S, Papatheodoridis G, Cortez-Pinto H, Silva AP, Rodrigues CMP, Valenti L, Pelusi S, Petta S, Pennisi G, Miele L, Liguori A, Geier A, Rau M, Trautwein C, Rei\u00dfing J, Aithal GP, Francis S, Palaniyappan N, Bradley C, Hockings P, Schneider M, Newsome PN, H\u00fcbscher S, Wenn D, Magnanensi J, Trylesinski A, Mayo R, Alonso C, Duffin K, Perfield JW, Chen Y, Hartman ML, Yunis C, Miller M, Chen Y, McLeod EJ, Ross T, Bernardo B, Sch\u00f6lch C, Ertle J, Younes R, Coxson H, Simon E, Gogain J, Ostroff R, Alexander L, Biegel H, Kj\u00e6r MS, Harder LM, Al-Sari N, Veidal SS, Oldenburger A, Ellegaard J, Balp M-M, Jennings L, Martic M, L\u00f6ffler J, Applegate D, Torstenson R, Lind\u00e9n D, Fournier-Poizat C, Llorca A, Kalutkiewicz M, Pepin K, Ehman R, Horan G, Ho G, Tai D, Chng E, Xiao T, Patterson SD, Billin A, Doward L, Twiss J, Thakker P, Derdak Z, Yashiro H, Landgren H, Lackner C, Gouw A, Hytiroglou P, Govaere O, Brass C, Tiniakos D, Perfield JW, Petsalaki E, Davidsen P, Vidal-Puig A, The LI (2024) An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD). Nat Metab 6:1178\u20131196","journal-title":"Nat Metab"},{"key":"621_CR30","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ebiom.2017.05.028","volume":"20","author":"L Xu","year":"2017","unstructured":"Xu L, Nagata N, Nagashimada M, Zhuge F, Ni Y, Chen G, Mayoux E, Kaneko S, Ota T (2017) SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice. EBioMedicine 20:137\u2013149","journal-title":"EBioMedicine"},{"key":"621_CR31","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12933-021-01237-2","volume":"20","author":"B Gaborit","year":"2021","unstructured":"Gaborit B, Ancel P, Abdullah AE, Maurice F, Abdesselam I, Calen A, Soghomonian A, Houssays M, Varlet I, Eisinger M, Lasbleiz A, Peiretti F, Bornet CE, Lefur Y, Pini L, Rapacchi S, Bernard M, Resseguier N, Darmon P, Kober F, Dutour A (2021) Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study. Cardiovasc Diabetol 20:57","journal-title":"Cardiovasc Diabetol"},{"key":"621_CR32","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1038\/oby.2012.59","volume":"20","author":"JJ Devenny","year":"2012","unstructured":"Devenny JJ, Godonis HE, Harvey SJ, Rooney S, Cullen MJ, Pelleymounter MA (2012) Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats. Obesity (Silver Spring) 20:1645\u20131652","journal-title":"Obesity (Silver Spring)"},{"key":"621_CR33","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s12576-010-0127-6","volume":"61","author":"K Iwata","year":"2011","unstructured":"Iwata K, Kinoshita M, Yamada S, Imamura T, Uenoyama Y, Tsukamura H, Maeda K-i (2011) Involvement of brain ketone bodies and the noradrenergic pathway in diabetic hyperphagia in rats. J Physiol Sci 61:103\u2013113","journal-title":"J Physiol Sci"},{"key":"621_CR34","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.2337\/db15-1356","volume":"65","author":"E Ferrannini","year":"2016","unstructured":"Ferrannini E, Baldi S, Frascerra S, Astiarraga B, Heise T, Bizzotto R, Mari A, Pieber TR, Muscelli E (2016) Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes 65:1190\u20131195","journal-title":"Diabetes"},{"key":"621_CR35","doi-asserted-by":"publisher","first-page":"5675","DOI":"10.3390\/ijms23105675","volume":"23","author":"R Kurtz","year":"2022","unstructured":"Kurtz R, Libby A, Jones BA, Myakala K, Wang X, Lee Y, Knoer G, Lo Cascio JN, McCormack M, Nguyen G, Choos END, Rodriguez O, Rosenberg AZ, Ranjit S, Albanese C, Levi M, Ecelbarger CM, Shepard BD (2022) Empagliflozin treatment attenuates hepatic steatosis by promoting white adipose expansion in obese TallyHo mice. Int J Mol Sci 23:5675","journal-title":"Int J Mol Sci"},{"key":"621_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2019.110539","volume":"498","author":"TI Petito-da-Silva","year":"2019","unstructured":"Petito-da-Silva TI, Souza-Mello V, Barbosa-da-Silva S (2019) Empaglifozin mitigates NAFLD in high-fat-fed mice by alleviating insulin resistance, lipogenesis and ER stress. Mol Cell Endocrinol 498:110539","journal-title":"Mol Cell Endocrinol"},{"key":"621_CR37","first-page":"63","volume":"52","author":"JS Thompson","year":"2002","unstructured":"Thompson JS, Brown SA, Khurdayan V, Zeynalzadedan A, Sullivan PG, Scheff SW (2002) Early effects of tribromoethanol, ketamine\/xylazine, pentobarbitol, and isoflurane anesthesia on hepatic and lymphoid tissue in ICR mice. Comp Med 52:63\u201367","journal-title":"Comp Med"},{"key":"621_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0117232","volume":"10","author":"KA Overmyer","year":"2015","unstructured":"Overmyer KA, Thonusin C, Qi NR, Burant CF, Evans CR (2015) Impact of anesthesia and euthanasia on metabolomics of mammalian tissues: studies in a C57BL\/6J mouse model. PLoS ONE 10:e0117232","journal-title":"PLoS ONE"},{"key":"621_CR39","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.metabol.2018.11.014","volume":"92","author":"SA Polyzos","year":"2019","unstructured":"Polyzos SA, Kountouras J, Mantzoros CS (2019) Obesity and nonalcoholic fatty liver disease: from pathophysiology to therapeutics. Metabolism 92:82\u201397","journal-title":"Metabolism"},{"key":"621_CR40","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s13679-023-00519-y","volume":"12","author":"ID Vachliotis","year":"2023","unstructured":"Vachliotis ID, Polyzos SA (2023) The role of tumor necrosis factor-alpha in the pathogenesis and treatment of nonalcoholic fatty liver disease. Curr Obes Rep 12:191\u2013206","journal-title":"Curr Obes Rep"},{"key":"621_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2023.155612","volume":"145","author":"HJ Chun","year":"2023","unstructured":"Chun HJ, Kim ER, Lee M, Choi DH, Kim SH, Shin E, Kim JH, Cho JW, Han DH, Cha BS, Lee YH (2023) Increased expression of sodium-glucose cotransporter 2 and O-GlcNAcylation in hepatocytes drives non-alcoholic steatohepatitis. Metabolism 145:155612","journal-title":"Metabolism"},{"key":"621_CR42","doi-asserted-by":"publisher","first-page":"904","DOI":"10.3390\/nu16060904","volume":"16","author":"S Kloock","year":"2024","unstructured":"Kloock S, Haerting N, Herzog G, Oertel M, Geiger N, Geier A, Sequeira V, Nickel A, Kohlhaas M, Fassnacht M, Dischinger U (2024) Effects of NPY-2 receptor antagonists, semaglutide, PYY(3\u201336), and empagliflozin on early MASLD in diet-induced obese rats. Nutrients 16:904","journal-title":"Nutrients"},{"key":"621_CR43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0151511","volume":"11","author":"C Komiya","year":"2016","unstructured":"Komiya C, Tsuchiya K, Shiba K, Miyachi Y, Furuke S, Shimazu N, Yamaguchi S, Kanno K, Ogawa Y (2016) Ipragliflozin improves hepatic steatosis in obese mice and liver dysfunction in type 2 diabetic patients irrespective of body weight reduction. PLoS ONE 11:e0151511","journal-title":"PLoS ONE"},{"key":"621_CR44","doi-asserted-by":"publisher","first-page":"58353","DOI":"10.18632\/oncotarget.16874","volume":"8","author":"K Obara","year":"2017","unstructured":"Obara K, Shirakami Y, Maruta A, Ideta T, Miyazaki T, Kochi T, Sakai H, Tanaka T, Seishima M, Shimizu M (2017) Preventive effects of the sodium glucose cotransporter 2 inhibitor tofogliflozin on diethylnitrosamine-induced liver tumorigenesis in obese and diabetic mice. Oncotarget 8:58353\u201358363","journal-title":"Oncotarget"},{"key":"621_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.761842","volume":"12","author":"K Fukushima","year":"2021","unstructured":"Fukushima K, Kitamura S, Tsuji K, Wada J (2021) Sodium-glucose cotransporter 2 inhibitors work as a \u201cregulator\u201d of autophagic activity in overnutrition diseases. Front Pharmacol 12:761842","journal-title":"Front Pharmacol"},{"key":"621_CR46","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1177\/1479164114563304","volume":"12","author":"P Lapuerta","year":"2015","unstructured":"Lapuerta P, Zambrowicz B, Strumph P, Sands A (2015) Development of sotagliflozin, a dual sodium-dependent glucose transporter 1\/2 inhibitor. Diab Vasc Dis Res 12:101\u2013110","journal-title":"Diab Vasc Dis Res"},{"key":"621_CR47","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.metabol.2015.11.006","volume":"65","author":"SA Polyzos","year":"2016","unstructured":"Polyzos SA, Kountouras J, Mantzoros CS (2016) Adipokines in nonalcoholic fatty liver disease. Metabolism 65:1062\u20131079","journal-title":"Metabolism"},{"key":"621_CR48","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1111\/jgh.15631","volume":"36","author":"V Potoupni","year":"2021","unstructured":"Potoupni V, Georgiadou M, Chatzigriva E, Polychronidou G, Markou E, Zapantis Gakis C, Filimidou I, Karagianni M, Anastasilakis D, Evripidou K, Ftergioti A, Togkaridou M, Tsaftaridis N, Apostolopoulos A, Polyzos SA (2021) Circulating tumor necrosis factor-\u03b1 levels in non-alcoholic fatty liver disease: a systematic review and a meta-analysis. J Gastroenterol Hepatol 36:3002\u20133014","journal-title":"J Gastroenterol Hepatol"},{"key":"621_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2023.102870","volume":"66","author":"K Burger","year":"2023","unstructured":"Burger K, Jung F, Baumann A, Brandt A, Staltner R, S\u00e1nchez V, Bergheim I (2023) TNF\u03b1 is a key trigger of inflammation in diet-induced non-obese MASLD in mice. Redox Biol 66:102870","journal-title":"Redox Biol"},{"key":"621_CR50","doi-asserted-by":"publisher","first-page":"G483","DOI":"10.1152\/ajpgi.00079.2013","volume":"305","author":"JR Clapper","year":"2013","unstructured":"Clapper JR, Hendricks MD, Gu G, Wittmer C, Dolman CS, Herich J, Athanacio J, Villescaz C, Ghosh SS, Heilig JS, Lowe C, Roth JD (2013) Diet-induced mouse model of fatty liver disease and nonalcoholic steatohepatitis reflecting clinical disease progression and methods of assessment. Am J Physiol Gastrointest Liver Physiol 305:G483-495","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"621_CR51","doi-asserted-by":"publisher","first-page":"9232","DOI":"10.1073\/pnas.0602956103","volume":"103","author":"C Le May","year":"2006","unstructured":"Le May C, Chu K, Hu M, Ortega CS, Simpson ER, Korach KS, Tsai MJ, Mauvais-Jarvis F (2006) Estrogens protect pancreatic beta-cells from apoptosis and prevent insulin-deficient diabetes mellitus in mice. Proc Natl Acad Sci U S A 103:9232\u20139237","journal-title":"Proc Natl Acad Sci U S A"},{"key":"621_CR52","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1475-2891-8-11","volume":"8","author":"J Hong","year":"2009","unstructured":"Hong J, Stubbins RE, Smith RR, Harvey AE, N\u00fa\u00f1ez NP (2009) Differential susceptibility to obesity between male, female and ovariectomized female mice. Nutr J 8:11","journal-title":"Nutr J"},{"key":"621_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2024.108024","volume":"186","author":"SA Polyzos","year":"2024","unstructured":"Polyzos SA, Goulis DG (2024) Menopause and metabolic dysfunction-associated steatotic liver disease. Maturitas 186:108024","journal-title":"Maturitas"}],"container-title":["Hormones"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-024-00621-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s42000-024-00621-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-024-00621-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T04:27:24Z","timestamp":1757132844000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s42000-024-00621-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,19]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["621"],"URL":"https:\/\/doi.org\/10.1007\/s42000-024-00621-3","relation":{},"ISSN":["1109-3099","2520-8721"],"issn-type":[{"value":"1109-3099","type":"print"},{"value":"2520-8721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,19]]},"assertion":[{"value":"30 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal procedures were carried out in accordance with the relevant National and European Union regulations and were approved by the General Directorate of Agriculture, Economy, and Veterinary Medicine of the region of Central Macedonia, Greece, which reviewed and approved the study. The study was also approved by the Bioethics Committee, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}